Media Center
Press Releases

Press Releases

31 Aug 16
Glioblastoma market set for strong innovation, with 120 first-in-class programs, says GBI Research

Glioblastoma, a particularly aggressive form of brain tumor, has a promising treatment pipeline, with 120 first-in-class programs acting on 86 first-in-class molecular targets, according to business intelligence provider GBI Research.

Read post
24 Aug 16
Diabetes and obesity therapeutics market will more than double to $163.2 billion by 2022, says GBI Research

The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%, according to business intelligence firm GBI Research.

Read post
22 Aug 16
Chronic pain treatment pipeline could yield innovative alternatives to opioids, says GBI Research

Although opioids continue to dominate the chronic pain market, adverse events associated with the drug such as the potential for abuse mean the treatment space is rife with unmet needs, which is encouraging pharmaceutical companies to explore innovative alternatives to opioids, according to business intelligence provider GBI Research.

Read post
17 Aug 16
Cystic fibrosis therapies will push Vertex ahead of GSK in $46.6 billion respiratory market by 2022, says GBI Research

The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably from $28.1 billion in 2015 to $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 7.5%, according to business intelligence provider GBI Research.

Read post
16 Aug 16
Unmet needs in rheumatoid arthritis treatment could be addressed by first-in-class pipeline, says GBI Research

The rheumatoid arthritis market is highly lucrative and significant advances in the understanding of the disease have greatly improved treatment options for a large number of patients over the past two decades. However, serious unmet needs remain, and there are still many opportunities for future drug developments, particularly for first-in-class innovation, according to business intelligence provider GBI Research.

Read post